- Home
- DNTH vs ONDS Comparison
DNTH vs ONDS Comparison
Compare DNTH & ONDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | ONDS |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.6B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DNTH | ONDS |
|---|---|---|
| Price | $86.57 | $9.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | ★ $121.00 | $19.83 |
| AVG Volume (30 Days) | 422.6K | ★ 54.8M |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.56 |
| Revenue | $2,036,000.00 | ★ $50,731,000.00 |
| Revenue This Year | N/A | $662.14 |
| Revenue Next Year | $29.48 | $76.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 605.31 |
| 52 Week Low | $16.77 | $0.89 |
| 52 Week High | $96.50 | $15.28 |
Technical Indicators
Market Signals| Indicator | DNTH | ONDS |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 45.35 |
| Support Level | $82.00 | $8.86 |
| Resistance Level | $90.23 | $11.87 |
| Average True Range (ATR) | 4.58 | 0.79 |
| MACD | -0.20 | -0.05 |
| Stochastic Oscillator | 52.27 | 13.69 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About ONDS Ondas Holdings Inc.
Ondas Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system. Geographically, the company operates in Israel, Germany, United Arab Emirates, United States, and Other Countries. It derives maximum revenue from Israel.